This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gordon, C. Articles by Clarke, A. E Search for Related Content PubMed PubMed Citation Articles by Gordon, C. Articles by Clarke, A. E Pubmed/NCBI databases Medline Plus Health Information Clinical Trials Lupus Social Bookmarking                         What's this?

Quality of life and economic evaluation in SLE clinical trials

Department of Rheumatology, Division of Immunity and Infection, Medical School, University of Birmingham, UK

Ann E Clarke

Divisions of Allergy/Clinical Immunology, Montreal, Quebec, Canada; Divison of Clinical Epidemiology, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4; Tel: (+1) 514 934 8292; Fax: (+1) 514 934 8293 annc{at}bic.mni.mcgill.ca

Outcome in SLE patients should include assessment of disease activity and chronic damage and also measurement of health-related quality of life and the economic impact of the disease. This paper reviews the methods available for doing this and the results of existing studies in SLE patients.

Key Words: systemic lupus erythematosus • quality of life • health status • direct medical costs • indirect costs

Lupus, Vol. 8, No. 8, 645-654 (1999)
DOI: 10.1191/096120399680411344


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]

				K. Dussan, L Magder, R. Brodsky, R. Jones, and M Petri High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures Lupus, December 1, 2008; 17(12): 1079 - 1085. [Abstract] [PDF]

				C. Gordon, D. J. Wallace, S. Shinada, K. C. Kalunian, L. Forbess, G. D. Braunstein, and M. H. Weisman Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus Rheumatology, March 1, 2008; 47(3): 334 - 338. [Abstract] [Full Text] [PDF]

				K Mcelhone, J Abbott, and L -S Teh A review of health related quality of life in systemic lupus erythematosus Lupus, October 1, 2006; 15(10): 633 - 643. [Abstract] [PDF]

				P. Panopalis, M. Petri, S. Manzi, D. A. Isenberg, C. Gordon, J.-L. Senecal, J. R. Penrod, L. Joseph, Y. St. Pierre, C. Pineau, et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being Rheumatology, June 1, 2005; 44(6): 751 - 755. [Abstract] [Full Text] [PDF]

				S. Rinaldi, A. Doria, F. Salaffi, M. Ermani, L. Iaccarino, A. Ghirardello, S. Zampieri, P. Sarzi-Puttini, P. F. Gambari, and G. Perini Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age Rheumatology, December 1, 2004; 43(12): 1574 - 1579. [Abstract] [Full Text] [PDF]

				A. Doria, S. Rinaldi, M. Ermani, F. Salaffi, L. Iaccarino, A. Ghirardello, S. Zampieri, S. Della Libera, G. Perini, and S. Todesco Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants Rheumatology, December 1, 2004; 43(12): 1580 - 1586. [Abstract] [Full Text] [PDF]

				J Schiffenbauer and L S Simon Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus, May 1, 2004; 13(5): 398 - 405. [Abstract] [PDF]

				V Strand Clinical trial design in systemic lupus erythematosus: lessons learned and future directions Lupus, May 1, 2004; 13(5): 406 - 411. [Abstract] [PDF]

				N A Dayal, C Gordon, L Tucker, and D A Isenberg The SLICC Damage Index: past, present and future Lupus, April 1, 2002; 11(4): 261 - 265. [PDF]

				S. J. Bowman, S. Pillemer, R. Jonsson, K. Asmussen, C. Vitali, R. Manthorpe, and N. Sutcliffe Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK Rheumatology, October 1, 2001; 40(10): 1180 - 1188. [Full Text] [PDF]